TPIV - TapImmune, Inc.

NasdaqCM - NasdaqCM Real Time Price. Currency in USD
8.34
+0.05 (+0.60%)
At close: 4:00PM EDT
Stock chart is not supported by your current browser
Previous Close8.29
Open8.26
Bid0.00 x 1200
Ask0.00 x 1100
Day's Range8.01 - 8.40
52 Week Range2.58 - 13.55
Volume100,153
Avg. Volume209,435
Market Cap376.341M
Beta (3Y Monthly)0.40
PE Ratio (TTM)N/A
EPS (TTM)-1.36
Earnings DateMay 29, 2018 - Jun 4, 2018
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est5.50
Trade prices are not sourced from all markets
  • TapImmune And Marker Therapeutics Announce Successful Closing Of Previously Announced Merger And Financing
    PR Newswire4 days ago

    TapImmune And Marker Therapeutics Announce Successful Closing Of Previously Announced Merger And Financing

    JACKSONVILLE, Fla., Oct. 17, 2018 /PRNewswire/ -- TapImmune Inc. (TPIV), today announced the closing of the previously announced merger with privately-held Marker Therapeutics, Inc.  In connection with the merger, TapImmune Inc. changed its name to Marker Therapeutics, Inc., and reincorporated from Nevada into Delaware.  The combined company will focus on the continued development and commercialization of T cell therapies.    Beginning Thursday, October 18, 2018, the Company's stock will begin trading under the new ticker symbol "MRKR" on the Nasdaq Capital Market and will have a new CUSIP number, 57055L 107.

  • TapImmune's HER2/neu-Targeted Breast Cancer Vaccine to be Studied in a Large Phase 2 Immunotherapy Combination Study Funded by an $11 Million U.S. Department of Defense Grant
    PR Newswire11 days ago

    TapImmune's HER2/neu-Targeted Breast Cancer Vaccine to be Studied in a Large Phase 2 Immunotherapy Combination Study Funded by an $11 Million U.S. Department of Defense Grant

    JACKSONVILLE, Fla., Oct. 10, 2018 /PRNewswire/ -- TapImmune Inc. (TPIV), a clinical-stage immuno-oncology company, congratulates Mayo Clinic for being awarded a grant of $11 million from the U.S. Department of Defense (DoD). This grant will cover the costs of a large Phase 2 study of TapImmune's HER2/neu-targeted breast cancer vaccine, TPIV110, in combination with another immunotherapeutic, trastuzumab (Herceptin®), for treating women with HER2/neu-positive breast cancer.

  • Who Really Owns TapImmune Inc (NASDAQ:TPIV)?
    Simply Wall St.26 days ago

    Who Really Owns TapImmune Inc (NASDAQ:TPIV)?

    The big shareholder groups in TapImmune Inc (NASDAQ:TPIV) have power over the company. Institutions often own shares in more established companies, while it’s not unusual to see insiders own aRead More...

  • TapImmune to Present at Two Upcoming Investor Conferences
    PR Newswire26 days ago

    TapImmune to Present at Two Upcoming Investor Conferences

    JACKSONVILLE, Fla. , Sept. 25, 2018 /PRNewswire/ -- TapImmune Inc. (NASDAQ: TPIV), a clinical-stage immuno-oncology company, today announced that its President and CEO, Peter L. Hoang , will participate ...

  • TapImmune To Present at 2018 Janney Healthcare Conference
    PR Newswirelast month

    TapImmune To Present at 2018 Janney Healthcare Conference

    JACKSONVILLE, Fla. , Sept. 12, 2018 /PRNewswire/ -- TapImmune Inc. (NASDAQ: TPIV), a clinical-stage immuno-oncology company, today announced that its President and CEO, Peter L. Hoang , will present at ...

  • ACCESSWIRE2 months ago

    Today’s Research Reports on Stocks to Watch: Innovate Biopharmaceuticals and TapImmune

    NEW YORK, NY / ACCESSWIRE / September 4, 2018 / Both Innovate Biopharmaceuticals and TapImmune sprang to life on Friday seeing big gains after the companies announced plans to present at conferences this ...

  • ACCESSWIRE2 months ago

    3 Cancer Treatment Stocks that Moved Higher in August

    Furthermore, many of the smaller biotechnology stocks have been garnering more interest for novel therapies and even more interest from some of their larger cohorts. A multi-million dollar strategic investment into one of the biotech companies this week has continued to emphasize the focus on the potential that smaller cap biotech companies hold. GT Biopharma (GTBP) for example is generating novel immuno-oncology biopharmaceutical drugs targeting cancers.

  • TapImmune to Participate at Two Upcoming Industry Conferences
    PR Newswire2 months ago

    TapImmune to Participate at Two Upcoming Industry Conferences

    JACKSONVILLE, Fla. , Aug. 29, 2018 /PRNewswire/ -- TapImmune Inc. (NASDAQ: TPIV), a clinical-stage immuno-oncology company, today announced that its President and CEO, Peter L. Hoang , will participate ...

  • PR Newswire3 months ago

    SHAREHOLDER ALERT: Monteverde & Associates PC Announces An Investigation Of Tapimmune, Inc. - TPIV

    NEW YORK, Aug. 3, 2018 /PRNewswire/ -- Juan Monteverde, founder and managing partner at Monteverde & Associates PC, a national securities firm headquartered at the Empire State Building in New York City, is investigating Tapimmune, Inc. ("Tapimmune" or the "Company") (TPIV) relating to the sale of the Company to a group of institutional investors. Pursuant to the Securities Purchase Agreements, the Purchasers have agreed to purchase 17,500,000 shares of the Company's common stock, par value $0.001, at $4.00 per share, for gross offering proceeds of $70 million.

  • ACCESSWIRE3 months ago

    Complimentary Technical Snapshots on Viking Therapeutics and Three More Biotech Stocks

    Stock Research Monitor: TPIV, VCEL, and VRTX LONDON, UK / ACCESSWIRE / July 25, 2018 / If you want a free Stock Review on VKTX sign up now at www.wallstequities.com/registration . On Tuesday, July 24, ...

  • TapImmune Stock: Why It Spiked 84% Last Week
    Market Realist4 months ago

    TapImmune Stock: Why It Spiked 84% Last Week

    TapImmune (TPIV) stock saw an ~84.1% hike during the week of June 1–8. On June 8, it closed at $9, which was a 249% growth from its 52-week low of $2.58 on April 23. On June 5 and June 6, TPIV stock had consistent growth of ~11.3% and ~11.2%, respectively. On June 8, TapImmune entered into security purchase agreements with some institutional and accredited investors related to the private placement of its equity securities.

  • ACCESSWIRE4 months ago

    Major Regulatory Changes & Recent FDA Win Could Create a 400%+ Gain For Investors Holding This Unknown Stock

    Remote patient monitoring, through smaller cheaper technology, is transforming medical care in the U.S. Cardiac care is a major beneficiary, and now major government agencies are signalling that this sector could be a top priority in the coming years. New medical device from Biotricity (BTCY) could shake up a handful of existing companies in cardiac remote monitoring, as their new device has some clear improvements over older technology. With revenue and new product announcements this year, BTCY could move significantly higher in 2018 and 2019.

  • ACCESSWIRE4 months ago

    Today’s Research Reports on Stocks to Watch: TapImmune and Intercept Pharmaceuticals

    NEW YORK, NY / ACCESSWIRE / June 11, 2018 / TapImmune and Intercept Pharmaceuticals were two biotech stocks heading higher in Friday trading. Intercept didn't have any particularly remarkable news but did announce that management would be presenting this Tuesday at the Goldman Sachs 39th Annual Global Healthcare Conference.

  • TapImmune Announces Pricing of $70 Million Private Placement
    PR Newswire4 months ago

    TapImmune Announces Pricing of $70 Million Private Placement

    JACKSONVILLE, Fla., June 8, 2018 /PRNewswire/ -- TapImmune Inc. (TPIV), a clinical-stage immuno-oncology company, today announced that it has entered into security purchase agreements with certain institutional and accredited investors in connection with a private placement of its equity securities. The private placement will be led by New Enterprise Associates (NEA) with participation from Aisling Capital and Perceptive Advisors, among other new and existing investors. The private placement is expected to be completed concurrently with the closing of the proposed merger between TapImmune Inc. and Marker Therapeutics, Inc., which was previously announced on May 15, 2018.

  • Benzinga5 months ago

    TapImmune Poised To Become A Cell Therapy Leader, WBB Securities Says In Upgrade

    TapImmune recently announced a merger agreement and reorganization with privately held Marker Therapeutics. The company then announced the formation of a Scientific Advisory Board after the close of the proposed merger May 16.

  • PR Newswire5 months ago

    TapImmune to Present at the Jefferies 2018 Global Healthcare Conference

    JACKSONVILLE, Fla. , May  31, 2018 /PRNewswire/ --  TapImmune Inc. (NASDAQ: TPIV), a clinical-stage immuno-oncology company, today announced that its President and CEO, Peter L. Hoang , will present at ...

  • PR Newswire5 months ago

    TapImmune to Present at 2018 Sachs Associates Immuno-Oncology BD&L and Investment Forum

    JACKSONVILLE, Fla. , May 30, 2018 /PRNewswire/ --  TapImmune Inc. (NASDAQ: TPIV), a clinical-stage immuno-oncology company, today announced that its President and CEO, Peter Hoang , will participate in ...

  • TapImmune to Host Investor Webinar on Thursday, May 24th to Discuss Proposed Merger with Marker Therapeutics and Its Transformational T Cell Therapy Platform
    PR Newswire5 months ago

    TapImmune to Host Investor Webinar on Thursday, May 24th to Discuss Proposed Merger with Marker Therapeutics and Its Transformational T Cell Therapy Platform

    JACKSONVILLE, Fla. , May 23, 2018 /PRNewswire/ -- TapImmune Inc. (NASDAQ: TPIV), a clinical-stage immuno-oncology company, announced today that Peter Hoang , President and CEO, will host a video webinar ...

  • TapImmune Expands Scientific Advisory Board with Cancer Immunotherapy Pioneers James P. Allison, Ph.D., and Padmanee Sharma, M.D., Ph.D., from the MD Anderson Cancer Center
    PR Newswire5 months ago

    TapImmune Expands Scientific Advisory Board with Cancer Immunotherapy Pioneers James P. Allison, Ph.D., and Padmanee Sharma, M.D., Ph.D., from the MD Anderson Cancer Center

    JACKSONVILLE, Fla., May 22, 2018 /PRNewswire/ -- TapImmune Inc. (TPIV), a clinical-stage immuno-oncology company, today announced that it has expanded its recently formed Scientific Advisory Board (SAB), which will become effective in conjunction with the proposed merger between the Company and Marker Therapeutics, Inc., and will support the continued clinical development of the Company's transformative, non-genetically engineered, multi-antigen T cell therapy platform. The new SAB members include leading experts from the University of Texas MD Anderson Cancer Center. James P. Allison, Ph.D., is a globally recognized tumor immunologist whose research led to the clinical development of the first FDA-approved cancer immunotherapy, ipilimumab (Yervoy®).

  • TapImmune Creates Scientific Advisory Board to Support Clinical Development of Multi-Antigen Cell Therapy Platform
    PR Newswire5 months ago

    TapImmune Creates Scientific Advisory Board to Support Clinical Development of Multi-Antigen Cell Therapy Platform

    JACKSONVILLE, Fla., May 16, 2018 /PRNewswire/ -- TapImmune Inc. (TPIV), a clinical-stage immuno-oncology company, today announced that it has assembled a Scientific Advisory Board (SAB) composed of leading experts in the field of immuno-oncology and cell therapy and that will become effective in conjunction with the proposed merger between the Company and Marker Therapeutics, Inc. The goal of the SAB will be to support the continued clinical development of the Company's transformative, non-genetically engineered, multi-antigen T cell therapy platform. Foundational members of the SAB include senior medical scientists from the Center for Cell and Gene Therapy at Baylor College of Medicine, including its founding Director and former President of the American Society for Gene and Cell Therapy (ASGCT) and of the International Society for Cell Therapy, Malcolm K. Brenner, M.D., Ph.D. Joining Dr. Brenner are colleagues Helen E. Heslop, M.D., D.Sc.

  • TapImmune to Host Investor Breakfast to Discuss Proposed Merger with Marker Therapeutics
    PR Newswire5 months ago

    TapImmune to Host Investor Breakfast to Discuss Proposed Merger with Marker Therapeutics

    Live Audio Webcast Scheduled for May 17th at 8:00 a.m. CT JACKSONVILLE, Fla. , May 15, 2018 /PRNewswire/ -- TapImmune Inc. (NASDAQ: TPIV), a leading clinical-stage immuno-oncology company, today announced ...

  • TapImmune and Marker Therapeutics Announce Entry into Merger Agreement, Creating a Transformational Immuno-Oncology Platform
    PR Newswire5 months ago

    TapImmune and Marker Therapeutics Announce Entry into Merger Agreement, Creating a Transformational Immuno-Oncology Platform

    JACKSONVILLE, Fla., May 15, 2018 /PRNewswire/ -- TapImmune Inc. (TPIV) ("TapImmune") today announced that it has entered into a definitive merger agreement to acquire Marker Therapeutics, Inc. ("Marker"), a privately-held clinical-stage developer of a transformative, non-genetically engineered, multi-antigen T cell therapy platform. The proposed transaction will be a merger-of-equals under which the stockholders of TapImmune and Marker will each own approximately 50% of the combined company, prior to any issuances of additional shares in a contemplated financing.